Leowin Healthcare LLP Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Leowin Healthcare LLP Pharmaceutical Export Portfolio Dataset — 5 Products, $280.2K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Leowin Healthcare LLP — Pharmaceutical Exporter Profile (2026) | 5 Products, $280.2K Trade | TransData Nexus

Leowin Healthcare LLP

Indian Pharmaceutical Exporter · Antiviral & HIV Medications Specialist · $280.2K Total Trade · DGFT Verified

Leowin Healthcare LLP is an Indian pharmaceutical exporter with a total trade value of $280.2K across 5 products in 2 therapeutic categories. Based on 149 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Sofosbuvir ($140.8K), Velpatasvir ($107.7K), Ledipasvir ($11.5K).

Leowin Healthcare LLP — Export Portfolio & Destination Treemap

Leowin Healthcare LLP pharmaceutical export portfolio — 5 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Leowin Healthcare LLP? — Company Overview & Market Position

Leowin Healthcare LLP, established on October 18, 2022, is a pharmaceutical company based in Gandhinagar, Gujarat, India. The company specializes in the trading and export of a diverse range of pharmaceutical products, including antiviral and oncology medications. Its registered office is located at Shop-265-266, The CBD Shopping Centre, Sardar Patel Ring Road, Gandhinagar, Gujarat, 382421.

The ownership structure of Leowin Healthcare LLP is predominantly held by its promoters, who own 92.83% of the company. The remaining shares are distributed among the public (4.10%) and other stakeholders (3.07%). The company's total obligation of contribution is ₹0.10 million, indicating a modest capital base. As of March 31, 2024, Leowin Healthcare LLP reported an annual turnover between ₹5 to ₹25 crore, reflecting its active engagement in the pharmaceutical trading sector.

What Does Leowin Healthcare LLP Export? — Product Portfolio Analysis

Top Products by Export Value

1Sofosbuvir$140.8K 2Velpatasvir

Product Portfolio — Top 5 by Export Value

Leowin Healthcare LLP exports 5 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Sofosbuvir	Antiviral & HIV Medications	$140.8K	70	0.3%	10
2	Velpatasvir	Antiviral & HIV Medications	$107.7K	48	0.4%	8
3	Ledipasvir	Antiviral & HIV Medications	$11.5K	10	1.0%	9
4	Raltegravir	Antiviral & HIV Medications	$10.8K	9	0.2%	6
5	Regorafenib	Advanced Oncology	$9.5K	12	0.9%	5

Leowin Healthcare LLP exports 5 pharmaceutical products across 2 therapeutic categories with a total export value of $280.2K. The top category is Antiviral & HIV Medications (96.6% of portfolio), followed by Advanced Oncology (3.4%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Leowin Healthcare LLP — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Leowin Healthcare LLP operates as a trader, wholesaler, and distributor of pharmaceutical products, rather than a manufacturer. The company sources its products from certified manufacturers to ensure quality and compliance with international standards. While specific details about manufacturing plant locations and capacities are not publicly disclosed, Leowin Healthcare emphasizes its commitment to delivering quality solutions by blending innovation, expertise, and customer-first values.

3Key Leadership

The leadership team at Leowin Healthcare LLP comprises experienced professionals dedicated to driving the company's growth and ensuring compliance with global healthcare standards. Key executives include:

Viveksingh Shambhuduttsingh Rajput: Designated Partner since October 18, 2022, with a focus on strategic operations and international business development.

Chitransh Sharma: Designated Partner since October 18, 2022, specializing in pharmaceutical product development and regulatory compliance.

Abhilash Gopalkrishna Panicker: Designated Partner since March 14, 2024, with expertise in pharmaceutical trading and global market strategies.

These leaders play critical roles in ensuring that Leowin Healthcare's products meet the highest standards of quality and adhere to regulatory requirements across different regions.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Leowin Healthcare LLP Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Leowin Healthcare LLP has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company exports a range of pharmaceutical products, such as Sofosbuvir, Velpatasvir, Ledipasvir, Raltegravir, and Regorafenib, primarily targeting antiviral and oncology therapeutic categories. Specific details regarding regulatory filings, approvals, and market access status in these regions are not publicly disclosed. However, Leowin Healthcare's commitment to quality and compliance suggests adherence to international regulatory standards.

2Emerging Markets

Leowin Healthcare LLP has expanded its reach into emerging markets, including Africa, Latin America, and Southeast Asia. The company's export data indicates shipments to countries such as Poland, Singapore, Laos, Tanzania, and Cambodia. While specific details about WHO prequalification are not available, the company's engagement in these regions suggests efforts to meet international standards for market access.

3Geographic Strategy

Leowin Healthcare LLP's geographic strategy appears to be focused on diversification, with exports to various countries across different continents. This approach helps mitigate concentration risk and positions the company to leverage growth opportunities in multiple markets. The strategic direction emphasizes expanding the company's global footprint while maintaining a focus on high-demand therapeutic areas such as antiviral and oncology medications.

Leowin Healthcare LLP — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Leowin Healthcare LLP's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. As a trader and distributor, the company likely collaborates with manufacturers who hold the necessary FDA approvals for their products. Leowin Healthcare's commitment to quality and compliance suggests adherence to FDA standards, but detailed records are not accessible.

2WHO & EU GMP

Leowin Healthcare LLP's website does not provide explicit information about WHO prequalification or EU Good Manufacturing Practice (GMP) certifications. As a distributor, the company sources products from certified manufacturers, which may hold these certifications. However, specific details regarding the manufacturers' certifications are not publicly disclosed. Leowin Healthcare's emphasis on quality and compliance indicates a commitment to international standards, but verifiable certifications are not available.

3CDSCO & Indian Regulatory

Leowin Healthcare LLP — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Leowin Healthcare LLP operates in a competitive pharmaceutical trading and export market, with numerous companies offering similar products in the antiviral and oncology therapeutic categories. While specific market share data is not available, the company's focus on high-demand medications such as Sofosbuvir, Velpatasvir, Ledipasvir, Raltegravir, and Regorafenib positions it to compete effectively. Leowin Healthcare's emphasis on quality, compliance, and strategic partnerships enhances its competitive standing in the global market.

2Key Differentiators

Leowin Healthcare LLP's key differentiators include its focus on high-demand therapeutic areas, such as antiviral and oncology medications, and its commitment to sourcing products from certified manufacturers. The company's strategic geographic diversification and emphasis on quality and compliance further distinguish it in the pharmaceutical trading and export sector.

3Strategic Position

Leowin Healthcare LLP's current strategic direction centers on trading and exporting generic pharmaceutical products, with a particular emphasis on antiviral and oncology medications. The company's future outlook involves expanding its global footprint, enhancing product offerings, and strengthening partnerships to meet the evolving needs of international markets.

Buyer Due Diligence Brief — Evaluating Leowin Healthcare LLP as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Leowin Healthcare LLP demonstrates a strong track record in pharmaceutical trading and export, with a total export value of $280,000 USD and 149 shipments across five products in two therapeutic categories. The company's export data indicates shipments to countries such as Poland, Singapore, Laos, Tanzania, and Cambodia, reflecting a consistent and reliable supply chain. Leowin Healthcare's commitment to quality and compliance further underscores its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and compliance:

FDA Approval: Confirm that the manufacturer's products are FDA-approved by checking the FDA's official website or contacting the manufacturer directly.

WHO-GMP Certification: Verify WHO-GMP certification by requesting the certificate from the manufacturer or checking the WHO's official website.

Frequently Asked Questions — Leowin Healthcare LLP

How many pharmaceutical products does Leowin Healthcare LLP export from India?

Leowin Healthcare LLP exports 5 pharmaceutical products across 2 therapeutic categories. The top exports are Sofosbuvir ($140.8K), Velpatasvir ($107.7K), Ledipasvir ($11.5K), Raltegravir ($10.8K), Regorafenib ($9.5K). Total export value is $280.2K.

What is Leowin Healthcare LLP's total pharmaceutical export value?

Leowin Healthcare LLP's total pharmaceutical export value is $280.2K, based on 149 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Leowin Healthcare LLP cover?

Leowin Healthcare LLP exports across 2 therapeutic categories. The largest are Antiviral & HIV Medications (96.6%, 4 products), Advanced Oncology (3.4%, 1 products).

Get Full Leowin Healthcare LLP Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.